Vaxcyte, Inc. $PCVX Shares Purchased by Strs Ohio

Strs Ohio boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 199.0% in the first quarter, Holdings Channel.com reports. The fund owned 30,800 shares of the company’s stock after buying an additional 20,500 shares during the quarter. Strs Ohio’s holdings in Vaxcyte were worth $1,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in shares of Vaxcyte by 30.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,565,036 shares of the company’s stock valued at $56,373,000 after purchasing an additional 366,266 shares during the last quarter. Pivotal bioVenture Partners Investment Advisor LLC grew its stake in Vaxcyte by 5.2% during the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,372,425 shares of the company’s stock worth $49,435,000 after buying an additional 67,300 shares during the last quarter. HighVista Strategies LLC grew its stake in Vaxcyte by 159.4% during the 3rd quarter. HighVista Strategies LLC now owns 86,802 shares of the company’s stock worth $3,127,000 after buying an additional 53,345 shares during the last quarter. Bridgefront Capital LLC increased its position in Vaxcyte by 127.2% during the third quarter. Bridgefront Capital LLC now owns 24,325 shares of the company’s stock worth $876,000 after buying an additional 13,617 shares during the period. Finally, NEXTBio Capital Management LP acquired a new position in Vaxcyte during the fourth quarter worth approximately $4,406,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In other news, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the sale, the chief financial officer owned 104,395 shares in the company, valued at $5,979,745.60. This represents a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total value of $126,742.50. Following the sale, the chief operating officer directly owned 156,760 shares of the company’s stock, valued at approximately $8,830,290.80. This represents a 1.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 75,448 shares of company stock worth $4,091,197 over the last 90 days. 3.30% of the stock is currently owned by insiders.

Vaxcyte Stock Up 1.9%

PCVX stock traded up $1.10 during trading on Tuesday, hitting $58.06. The company had a trading volume of 66,886 shares, compared to its average volume of 1,494,090. The firm has a market cap of $8.38 billion, a PE ratio of -8.42 and a beta of 1.22. Vaxcyte, Inc. has a 1-year low of $29.08 and a 1-year high of $65.00. The firm has a 50-day moving average price of $52.21 and a 200-day moving average price of $53.47.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the prior year, the business earned ($1.04) earnings per share. Sell-side analysts anticipate that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on PCVX. Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Finally, Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $86.00.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.